#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Anal fistula Ocular lymphoma Waldenstrom's macroglobulinaemia Small cell lung cancer recurrent Transplant rejection Pulmonary sarcoidosis Henoch-Schonlein purpura Microscopic polyangiitis Biliary neoplasm Dedifferentiated liposarcoma Angiosarcoma Neuroendocrine cell hyperplasia of infancy Systemic candida Cervix carcinoma recurrent Marfan's syndrome More trials…

    Learn about Rare Diseases

    Pelizaeus-Merzbacher disease – Trials in Disease Glomerulonephritis membranous – Basic Information Chronic granulomatous disease – Trials in Disease Lymphangioma – Life with Disease Mantle cell lymphoma stage IV – Trials in Disease Richter’s syndrome – Life with Disease Haemophagocytic lymphohistiocytosis Paraneoplastic neurological syndrome – Life with Disease Sjogren’s syndrome – Trials in Disease Castleman’s disease – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    IMA401 Nmd670 Domvanalimab RP3 Artemisia Vulgaris (312) Levothyroxine Sodium Cariprazine Hydrochloride VELPATASVIR Roflumilast Abc-23A-116 Difelikefalin Danicamtiv Rilpivirine Mk-2060 4-Hydroxy-N-Desmethyltamoxifen VAMIFEPORT TRIHYDROCHLORIDE Cctx-001 Nitrofurantoin Axatilimab AGANIRSEN More therapies…

    Learn about Your Condition

    Diverticulitis Pulmonary alveolar haemorrhage Drug use disorder Thalassaemia Bronchopulmonary dysplasia Multiple sclerosis relapse Renal injury Short-bowel syndrome Vulval cancer Progressive multiple sclerosis Pelvic venous thrombosis Kaposi's sarcoma Pancreatic neoplasm Metabolic syndrome Carotid artery stenosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Chronic spontaneous urticaria

  • Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

    Recruiting

    3 1 1
    Investigated Drugs:
    • Remibrutinib
    Bulgaria Czechia France Germany Poland Spain

  • A study to evaluate the efficacy and safety of lesigercept in adults with chronic spontaneous urticaria who do not have enough relief from antihistamines

    Recruiting

    2 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Bulgaria Poland

  • A study to evaluate the effectiveness and safety of ritlecitinib tosilate and loratadine in adults with chronic spontaneous urticaria (hives)

    Recruiting

    2 1 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Investigated Drugs:
    • Loratadine
    Bulgaria Germany Poland Spain

  • Study of tildrakizumab to treat patients with chronic spontaneous urticaria who did not respond to previous treatments

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Investigated Drugs:
    • Tildrakizumab
    Germany

  • A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Barzolvolimab
    • Epinephrine
    Belgium Bulgaria Croatia Czechia Denmark France +10

  • Study on the Effects of EVO756 in Adults with Moderate to Severe Chronic Spontaneous Urticaria

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Investigated Drugs:
    • Placebo
    Bulgaria Germany Hungary Italy Poland Spain
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!